 WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 02, 2022 GLOBE NEWSWIRE -- iTeos Therapeutics, Inc. Nasdaq: ITOS, a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, PhD, President and Chief Executive Officer, will participate in a panel discussion at the upcoming 2022 Wedbush PacGrow Healthcare Conference titled: IOs Wide Open Opportunities and Challenges in Immuno-Oncology on Tuesday, August 9, 2022 at 8:00 a.m. ET. 